Pterostilbene Nanoparticles Downregulate Hypoxia-Inducible Factors in Hepatoma Cells Under Hypoxic Conditions

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Song DS, Nam SW, Bae SH, et al. Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma. World J Gastroenterol. 2015;21:2395–2404. doi:10.3748/wjg.v21.i8.2395
   PubMedGoogle Scholar
• Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol. 2015;21:10327–10335. doi:10.3748/wjg.v21.i36.10327
   PubMed Web of Science ®Google Scholar
• Lin D, Wu J. Hypoxia inducible factor in hepatocellular carcinoma: a therapeutic target. World J Gastroenterol. 2015;21:12171–12178. doi:10.3748/wjg.v21.i42.12171
   PubMed Web of Science ®Google Scholar
• Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004;10:2878–2882. doi:10.3748/wjg.v10.i19.2878
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257. doi:10.1038/35025220
   PubMed Web of Science ®Google Scholar
• Wang B, Xu H, Gao ZQ, Ning HF, Sun YQ, Cao GW. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol. 2008;49:523–529. doi:10.1080/02841850801958890
   PubMed Web of Science ®Google Scholar
• Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM. The changes of HIF-1alpha and VEGF expression after TACE in patients with hepatocellular carcinoma. J Clin Med Res. 2016;8:297–302. doi:10.14740/jocmr2496w
   PubMedGoogle Scholar
• Liu WR, Jin L, Tian MX, et al. Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2016;40:169–178. doi:10.1016/j.clinre.2015.06.017
   PubMedGoogle Scholar
• Mao X, Wong SY, Tse EY, et al. Mechanisms through which hypoxia-induced caveolin-1 drives tumorigenesis and metastasis in hepatocellular carcinoma. Cancer Res. 2016;76:7242–7253. doi:10.1158/0008-5472.CAN-16-1031
   PubMedGoogle Scholar
• Edlich F. BCL-2 proteins and apoptosis: recent insights and unknowns. Biochem Biophys Res Commun. 2018;500:26–34. doi:10.1016/j.bbrc.2017.06.190
   PubMed Web of Science ®Google Scholar
• Shajahan AN, Dobbin ZC, Hickman FE, Dakshanamurthy S, Clarke R. Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK). J Biol Chem. 2012;287:17682–17692. doi:10.1074/jbc.M111.304022
   PubMedGoogle Scholar
• Kudo M, Ueshima K, Ikeda M, et al.; group, T. s. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69:1492–1501. doi:10.1136/gutjnl-2019-318934.
   PubMed Web of Science ®Google Scholar
• Pinter M, Hucke F, Graziadei I, et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology. 2012;263:590–599. doi:10.1148/radiol.12111550
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390. doi:10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Liao CY, Lee CC, Tsai CC, et al. Novel investigations of flavonoids as chemopreventive agents for hepatocellular carcinoma. Biomed Res Int. 2015;2015:840542. doi:10.1155/2015/840542
   PubMedGoogle Scholar
• Estrela JM, Ortega A, Mena S, Rodriguez ML, Asensi M. Pterostilbene: biomedical applications. Crit Rev Clin Lab Sci. 2013;50:65–78. doi:10.3109/10408363.2013.805182
   PubMed Web of Science ®Google Scholar
• Chen RJ, Kuo HC, Cheng LH, et al. Apoptotic and nonapoptotic activities of pterostilbene against cancer. Int J Mol Sci. 2018;19. doi:10.3390/ijms19010287.
   Web of Science ®Google Scholar
• Lee PS, Chiou YS, Ho CT, Pan MH. Chemoprevention by resveratrol and pterostilbene: targeting on epigenetic regulation. Biofactors. 2018;44:26–35. doi:10.1002/biof.1401
   PubMed Web of Science ®Google Scholar
• Yu CL, Yang SF, Hung TW, Lin CL, Hsieh YH, Chiou HL. Inhibition of eIF2alpha dephosphorylation accelerates pterostilbene-induced cell death in human hepatocellular carcinoma cells in an ER stress and autophagy-dependent manner. Cell Death Dis. 2019;10:418. doi:10.1038/s41419-019-1639-5
   PubMedGoogle Scholar
• Lin WS, Leland JV, Ho CT, Pan MH. Occurrence, bioavailability, anti-inflammatory, and anticancer effects of pterostilbene. J Agric Food Chem. 2020. doi:10.1021/acs.jafc.9b07860
   Google Scholar
• Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727. doi:10.5402/2012/195727
   PubMedGoogle Scholar
• Peng RM, Lin GR, Ting Y, Hu JY. Oral delivery system enhanced the bioavailability of stilbenes: resveratrol and pterostilbene. Biofactors. 2018;44:5–15. doi:10.1002/biof.1405
   PubMedGoogle Scholar
• Summerlin N, Soo E, Thakur S, Qu Z, Jambhrunkar S, Popat A. Resveratrol nanoformulations: challenges and opportunities. Int J Pharm. 2015;479:282–290. doi:10.1016/j.ijpharm.2015.01.003
   PubMed Web of Science ®Google Scholar
• Roberts MS, Mohammed Y, Pastore MN, et al. Topical and cutaneous delivery using nanosystems. J Control Release. 2017;247:86–105. doi:10.1016/j.jconrel.2016.12.022
   PubMed Web of Science ®Google Scholar
• Singh V, Chaudhary AK. Preparation of Eudragit E100 microspheres by modified solvent evaporation method. Acta Pol Pharm. 2011;68:975–980.
   PubMedGoogle Scholar
• Huang PH, Hu SC, Lee CW, Yeh AC, Tseng CH, Yen FL. Design of acid-responsive polymeric nanoparticles for 7,3ʹ,4ʹ-trihydroxyisoflavone topical administration. Int J Nanomedicine. 2016;11:1615–1627. doi:10.2147/IJN.S100418
   PubMedGoogle Scholar
• Lee YH, Chen YY, Yeh YL, Wang YJ, Chen RJ. Stilbene compounds inhibit tumor growth by the induction of cellular senescence and the inhibition of telomerase activity. Int J Mol Sci. 2019;20. doi:10.3390/ijms20112716.
   Google Scholar
• Wang P, Sang S. Metabolism and pharmacokinetics of resveratrol and pterostilbene. Biofactors. 2018;44:16–25. doi:10.1002/biof.1410
   PubMed Web of Science ®Google Scholar
• Hsu W-C, Ng L-T, Wu T-H, Lin L-T, Yen F-L, Lin -C-C. Characteristics and antioxidant activities of silymarin nanoparticles. J Nanosci Nanotechnol. 2012;12(3):2022–2027. doi:10.1166/jnn.2012.5173
   PubMedGoogle Scholar
• Huang PH, Hu SCS, Yen FL, Tseng CH. Improvement of skin penetration, antipollutant activity and skin hydration of 7,3ʹ,4ʹ-trihydroxyisoflavone cyclodextrin inclusion complex. Pharmaceutics. 2019;11:399. doi:10.3390/pharmaceutics11080399
   PubMedGoogle Scholar
• Sun J, Wang F, Sui Y, et al. Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q(1)(0) as naked nanocrystals. Int J Nanomedicine. 2012;7:5733–5744. doi:10.2147/IJN.S34365
   PubMed Web of Science ®Google Scholar
• Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385:113–142. doi:10.1016/j.ijpharm.2009.10.018
   PubMed Web of Science ®Google Scholar
• An JH, Lim C, Kiyonga AN, et al. Co-amorphous screening for the solubility enhancement of poorly water-soluble mirabegron and investigation of their intermolecular interactions and dissolution behaviors. Pharmaceutics. 2018;10:149. doi:10.3390/pharmaceutics10030149
   PubMed Web of Science ®Google Scholar
• Li B, Wen M, Li W, He M, Yang X, Li S. Preparation and characterization of baicalin-poly -vinylpyrrolidone coprecipitate. Int J Pharm. 2011;408:91–96. doi:10.1016/j.ijpharm.2011.01.055
   PubMed Web of Science ®Google Scholar
• Khutoryanskiy VV. Hydrogen-bonded interpolymer complexes as materials for pharmaceutical applications. Int J Pharm. 2007;334:15–26. doi:10.1016/j.ijpharm.2007.01.037
   PubMed Web of Science ®Google Scholar
• Guo L, Tan K, Wang H, Zhang X. Pterostilbene inhibits hepatocellular carcinoma through p53/SOD2/ROS-mediated mitochondrial apoptosis. Oncol Rep. 2016;36:3233–3240. doi:10.3892/or.2016.5151
   PubMedGoogle Scholar
• Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117–2127. doi:10.1016/j.ejca.2011.05.007
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol. 2016;64:1090–1098. doi:10.1016/j.jhep.2016.01.012
   PubMed Web of Science ®Google Scholar
• Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, Phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:565–575. doi:10.1016/S2468-1253(17)30156-5
   PubMed Web of Science ®Google Scholar
• Kudo M, Han G, Finn RS, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology. 2014;60:1697–1707. doi:10.1002/hep.27290
   PubMed Web of Science ®Google Scholar
• Kudo M, Cheng AL, Park JW, et al. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet Gastroenterol Hepatol. 2018;3:37–46. doi:10.1016/S2468-1253(17)30290-X
   PubMed Web of Science ®Google Scholar
• Kudo M, Arizumi T. Transarterial chemoembolization in combination with a molecular targeted agent: lessons learned from negative trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2). Oncology. 2017;93(Suppl 1):127–134. doi:10.1159/000481243
   PubMed Web of Science ®Google Scholar
• Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing “preassembled signaling complexes” at the plasma membrane. J Biol Chem. 1998;273:5419–5422. doi:10.1074/jbc.273.10.5419
   PubMed Web of Science ®Google Scholar
• Filippini A, Sica G, D’Alessio A. The caveolar membrane system in endothelium: from cell signaling to vascular pathology. J Cell Biochem. 2018;119:5060–5071. doi:10.1002/jcb.26793
   PubMedGoogle Scholar
• Castillo Bennett J, Silva P, Martinez S, Torres VA, Quest AFG. Hypoxia-induced caveolin-1 expression promotes migration and invasion of tumor cells. Curr Mol Med. 2018;18:199–206. doi:10.2174/1566524018666180926163218
   PubMedGoogle Scholar
• Zhou Q, Peng X, Liu X, et al. FAT10 attenuates hypoxia-induced cardiomyocyte apoptosis by stabilizing caveolin-3. J Mol Cell Cardiol. 2018;116:115–124. doi:10.1016/j.yjmcc.2018.02.008
   PubMedGoogle Scholar